Adicet Bio, Inc.
NASDAQ Global MarketTotal Valuation
Adicet Bio, Inc. carries a market capitalization of 73.20M, placing it among publicly traded companies globally. Its enterprise value stands at -68.37M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 73.20M |
| Enterprise Value | -68.37M |
Share Statistics
Adicet Bio, Inc. currently has 9.60M shares outstanding.
| Shares Outstanding | 9.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.09 |
| P/TBV Ratio | 0.40 |
| P/FCF Ratio | -0.61 |
| P/OCF Ratio | -0.61 |
Financial Position
Adicet Bio, Inc. maintains a current ratio of 7.65, meaning it holds 7.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.92, indicating elevated leverage, while an interest coverage ratio of -1,826.39 demonstrates limited ability to service its debt obligations.
| Current Ratio | 7.65 |
| Quick Ratio | 7.54 |
| Debt / Equity | 9.92 |
| Debt / EBITDA | -0.13 |
| Interest Coverage | -1,826.39 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -60.35 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Adicet Bio, Inc.'s stock has declined approximately -37.15891% over the past 52 weeks. The 50-day moving average sits at 7.68, while the 200-day moving average is 9.47.
| Beta (5Y) | N/A |
| 52-Week Price Change | -37.15891% |
| 50-Day Moving Average | 7.68 |
| 200-Day Moving Average | 9.47 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -107.76M, while operating income came in at -113.80M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -113.80M |
| Pretax Income | -108.83M |
| Net Income | -108.83M |
| EBITDA | -107.76M |
| EBIT | -113.80M |
| Earnings Per Share (EPS) | -13.40 |
Balance Sheet
Adicet Bio, Inc. holds 137.59M in cash and equivalents against 13.90M in total debt, resulting in a net debt position of -36.24M. Total book value stands at -634.94M, with working capital of 121.77M providing operational flexibility.
| Cash & Cash Equivalents | 137.59M |
| Total Debt | 13.90M |
| Net Debt | -36.24M |
| Equity (Book Value) | -634.94M |
| Book Value Per Share | -78.15 |
| Working Capital | 121.77M |
Cash Flow
Adicet Bio, Inc. produced -91.34M in operating cash flow over the past twelve months. After subtracting -283,000.00 in capital expenditures, free cash flow totaled -91.62M - equivalent to -11.28 per share.
| Operating Cash Flow | -91.34M |
| Capital Expenditures | -283,000.00 |
| Free Cash Flow | -91.62M |
| FCF Per Share | -11.28 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -136.07 |
| FCF Yield | -164.58 |
Stock Splits
Adicet Bio, Inc.'s most recent stock split took place on December 30, 2025 with a 16:1 split ratio.
| Last Split Date | 12/30/2025 |
| Split Ratio | 16:1 |
Scores
Adicet Bio, Inc. posts an Altman Z-Score of -5.47, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.47 |